Follow-on biologic user fees (clarification)
Executive Summary
Recently introduced legislation creating an approval pathway for follow-on biologics will apply user fees for such applications. Both the House and Senate versions of the "Access to Life-Saving Medicine Act" create a new subsection under Section 351 of the Public Health Service Act for follow-on biologics applications. The Prescription Drug User Fee Act applies to all applications submitted under Section 351. A previous story in "The Pink Sheet" stated that the bill was "silent" on user fees (1"The Pink Sheet" Oct. 9, 2006, p. 5)...
You may also be interested in...
Biogenerics Bill Differs From ANDA System In Exclusivity, Patent Listing
Recently introduced follow-on biologics legislation has several characteristics that make it distinct from the current approval pathway for generic drug
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.